BioInformant
@StemCellMarket
Followers
19K
Following
6K
Media
2K
Statuses
16K
Cade Hildreth, Founder: As the 1ST and ONLY market research firm to specialize in the #stemcell industry, BioInformant has been cited by WSJ, Xconomy, & Vogue.
Washington, DC
Joined July 2014
FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia - https://t.co/JbPfhSNKwR
@GamidaCellTx
0
1
0
Cellistic Launches Three New iPSC-based GMP Manufacturing Platforms to advance Immuno-Oncology and Regenerative Cell Therapies - https://t.co/BSa4Pe01kZ
@CellisticCT
0
0
0
We continue to be awed by @RoosterBio's leadership in cell culture innovation and the way they simplify processes while enabling scalability: Generate Billions of Xeno-Free Fibroblasts for Your R&D Program: https://t.co/5ii06wvqkc
0
1
3
WORD+2026 Connecting Global NAM Research. #Bettertogether Organoids, Organ-on-a-Chip, Assembloids and innovative NAMS - https://t.co/x2u6cKATfJ In just three weeks time, the 5th WORD+ event brings together leading researchers, societies and technologies in Cambridge, U.K.
0
0
0
The Jackson Laboratory receives an up to $30 million contract award to revolutionize drug safety testing with AI-powered “virtual hearts” - https://t.co/oqO8QkM296
@jacksonlab
0
0
1
Kobe University Introduces a Simplified Cryopreservation Method for iPSCs - https://t.co/I7Si1wXGLo
0
0
0
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering - https://t.co/UAiJFMvgtA
@abbvie @bmsnews @KitePharma @AstraZeneca @InteriusBio
0
0
0
TheWell Bioscience and PeptiGrowth Enter into Marketing Collaboration Agreement to Advance Next-Generation Cell Culture Solutions - https://t.co/PfUKHmAvPp
@TheWellBio
0
0
0
10 Cell Therapy Stocks That Will Be Intriguing to Watch in 2026 - https://t.co/e3k1jr4y3y
@Capricor @healiospr @CellBioMedGroup @GamidaCellTx @Mesoblast @Pluribiotech @REGENXBIO @Vistagen
0
0
2
GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL: A Cost-Optimized Approach - https://t.co/a2GV9gl0DN
@_REPROCELL
0
0
0
Congratulations to the PeptiGrowth Inc. team on the launch of its IL-15 alternative peptide, an exciting advance in synthetic growth factor technology. PeptiGrowth Inc. is Launching a Novel Synthetic Peptide: IL-15 alternative peptide - https://t.co/60OBHq8yjr
0
0
0
Novo Withdraws from $598M Heartseed Partnership; Pursues Short-Term Profit Over iPSC Potential - https://t.co/5KmWA6vr0I
@novonordisk
0
0
0
Curi Bio Secures $10M Series B to Scale Human-Relevant iPSC-Based Preclinical Platforms and Advanced Data Analysis for Drug Discovery - https://t.co/PKORIR79kR
@Curi_Bio
0
0
0
What has 2025 taught us about stem cell innovation and market dynamics? - https://t.co/kq6juZk99R
0
0
0
BMS Makes a Bold Leap into CAR-T Buying Orbital Therapeutics for $1.5B - https://t.co/kxk3LZSNxc
@bmsnews
0
0
1
A Spark Becomes a Surge: How Ryoncil Reignited MSC Development - https://t.co/sQdjtZe3rG
@Mesoblast
0
0
2
A Complete Guide to Induced Pluripotent Stem Cell (iPSC) Core Facilities- https://t.co/OSuIwgVEnF
@PennMedicine @CedarsSinai @Cornell @UNC_SOM @harvardstemcell @washumedicine @JoslinDiabetes @GeorgiaTech @MIT_Picower @UofDenver @SCICambridge @Penn @salkinstitute @YaleMed @UWISCRM
0
1
1
The Future of Stem Cell Therapeutics – Balancing Safety and Efficacy - https://t.co/GjSJrqNzGs
0
0
0
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting #Exosome Drug Delivery Platform - https://t.co/Mu06OamnE7
0
0
1
Big Pharma Makes M&A Moves to Secure Positions in In Vivo Cell Engineering - https://t.co/UAiJFMvgtA
@abbvie @bmsnews @KitePharma @InteriusBio @AstraZeneca
0
0
1